Artificial Intelligence In Drug Discovery Market Size, Share & Trends Report

Artificial Intelligence In Drug Discovery Market Size, Share & Trends Analysis Report By Therapeutic Space (Oncology, Neurodegenerative Diseases), By Application, By Region, And Segment Forecasts, 2024 - 2030

Report ID: GVR-4-68039-029-7
Number of Report Pages: 80
Format: PDF, Horizon Databook

Historical Range: 2018 - 2022
Forecast Period: 2024 - 2030
Industry: Healthcare

Market Segmentation

Artificial Intelligence (AI) in Drug Discovery Application Outlook (Revenue, USD Million, 2018 - 2030)
- Drug optimization and repurposing
- Preclinical testing
- Others
Artificial Intelligence (AI) in Drug Discovery Therapeutic Area Outlook (Revenue, USD Million, 2018 - 2030)
- Oncology
- Neurodegenerative Diseases
- Cardiovascular Disease
- Metabolic Diseases
- Infectious Disease
- Others
Artificial Intelligence (AI) in Drug Discovery Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America AI in Drug Discovery Application Outlook
    - Drug optimization and repurposing
    - Preclinical testing
    - Others
  - North America AI in Drug Discovery Therapeutic Space
    - Oncology
    - Neurodegenerative Diseases
    - Cardiovascular Disease
    - Metabolic Diseases
    - Infectious Disease
    - Others
  - U.S.
    - U.S. AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - U.S. AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Canada
    - Canada AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Canada AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Mexico
    - Mexico AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Mexico AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
- Europe
  - Europe AI in Drug Discovery Application Outlook
    - Drug optimization and repurposing
    - Preclinical testing
    - Others
  - Europe AI in Drug Discovery Therapeutic Space
    - Oncology
    - Neurodegenerative Diseases
    - Cardiovascular Disease
    - Metabolic Diseases
    - Infectious Disease
    - Others
  - UK
    - UK AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - UK AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Germany
    - Germany AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Germany AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - France
    - France AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - France AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Italy
    - Italy AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Italy AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Spain
    - Spain AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Spain AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Denmark
    - Denmark AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Denmark AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Sweden
    - Sweden AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Sweden AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Norway
    - Norway AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Norway AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
- Asia Pacific
  - Asia Pacific AI in Drug Discovery Application Outlook
    - Drug optimization and repurposing
    - Preclinical testing
    - Others
  - Asia Pacific AI in Drug Discovery Therapeutic Space
    - Oncology
    - Neurodegenerative Diseases
    - Cardiovascular Disease
    - Metabolic Diseases
    - Infectious Disease
    - Others
  - Japan
    - Japan AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Japan AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - China
    - China AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - China AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - India
    - India AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - India AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - South Korea
    - South Korea AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - South Korea AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Australia
    - Australia AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Australia AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
- Latin America
  - Latin America AI in Drug Discovery Application Outlook
    - Drug optimization and repurposing
    - Preclinical testing
    - Others
  - Latin America AI in Drug Discovery Therapeutic Space
    - Oncology
    - Neurodegenerative Diseases
    - Cardiovascular Disease
    - Metabolic Diseases
    - Infectious Disease
    - Others
  - Brazil
    - Brazil AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Brazil AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Argentina
    - Argentina AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Argentina AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
- MEA
  - MEA AI in Drug Discovery Application Outlook
    - Drug optimization and repurposing
    - Preclinical testing
    - Others
  - MEA AI in Drug Discovery Therapeutic Space
    - Oncology
    - Neurodegenerative Diseases
    - Cardiovascular Disease
    - Metabolic Diseases
    - Infectious Disease
    - Others
  - South Africa
    - South Africa AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - South Africa AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Saudi Arabia
    - Saudi Arabia AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Saudi Arabia AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - UAE
    - UAE AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - UAE AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others
  - Kuwait
    - Kuwait AI in Drug Discovery Application Outlook
      - Drug optimization and repurposing
      - Preclinical testing
      - Others
    - Kuwait AI in Drug Discovery Therapeutic Space
      - Oncology
      - Neurodegenerative Diseases
      - Cardiovascular Disease
      - Metabolic Diseases
      - Infectious Disease
      - Others

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.